Biotech ETFs trailed the S&P 500 a lot as the companies suffered from rising rates. But a wave of deals beginning in October gave new life to the sector.
Shanghai-based Gracell Biotechnologies is being acquired by AstraZeneca in a deal valued at up to $1.2 billion, a report says Synopsys and Ansys are in.